|
Infarction, Middle Cerebral Artery
|
0.200 |
Biomarker
|
disease |
RGD |
Neurovascular protection in voltage-gated proton channel Hv1 knock-out rats after ischemic stroke: interaction with Na
|
31250553 |
2019 |
|
Eosinophil count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
JOUBERT SYNDROME 13
|
0.100 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Brain Ischemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
VSOP/Hv1 is a potential therapeutic target for brain ischemia, since Hvcn1 deficiency reduces microglial ROS production and protects brain from neuronal damage (Wu et al.).
|
28628214 |
2017 |
|
Lymphoma
|
0.010 |
GeneticVariation
|
group |
BEFREE |
This study expands the number of mutated genes described in several known signaling pathways and complexes involved in lymphoma pathogenesis (BCR, Notch, SWitch/sucrose nonfermentable (SWI/SNF), vacuolar ATPases) and identified novel recurrent mutations (EGR1/2, POU2AF1, BTK, ZNF608, HVCN1) that require further investigation in the context of FL biology, prognosis, and treatment.
|
28064239 |
2017 |
|
Lymphoma, Follicular
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study expands the number of mutated genes described in several known signaling pathways and complexes involved in lymphoma pathogenesis (BCR, Notch, SWitch/sucrose nonfermentable (SWI/SNF), vacuolar ATPases) and identified novel recurrent mutations (EGR1/2, POU2AF1, BTK, ZNF608, HVCN1) that require further investigation in the context of FL biology, prognosis, and treatment.
|
28064239 |
2017 |
|
Adult Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This study expands the number of mutated genes described in several known signaling pathways and complexes involved in lymphoma pathogenesis (BCR, Notch, SWitch/sucrose nonfermentable (SWI/SNF), vacuolar ATPases) and identified novel recurrent mutations (EGR1/2, POU2AF1, BTK, ZNF608, HVCN1) that require further investigation in the context of FL biology, prognosis, and treatment.
|
28064239 |
2017 |
|
Childhood Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This study expands the number of mutated genes described in several known signaling pathways and complexes involved in lymphoma pathogenesis (BCR, Notch, SWitch/sucrose nonfermentable (SWI/SNF), vacuolar ATPases) and identified novel recurrent mutations (EGR1/2, POU2AF1, BTK, ZNF608, HVCN1) that require further investigation in the context of FL biology, prognosis, and treatment.
|
28064239 |
2017 |
|
Channelopathies
|
0.010 |
Biomarker
|
disease |
BEFREE |
In an attempt to identify specific channels, we tested neutrophils from knock-out mouse models including CLIC1, ClC3, ClC4, ClC7, KCC3, KCNQ1, KCNE3, KCNJ15, TRPC1/3/5/6, TRPA1/TRPV1, TRPM2, and TRPV2, and double knockouts of CLIC1, ClC3, KCC3, TRPM2, and KCNQ1 with HVCN1, and humans with channelopathies involving BEST1, ClC7, CFTR, and MCOLN1.
|
28293191 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
HVCN1 is expressed in malignant B cells that rely on BCR signaling, such as chronic lymphocytic leukemia (CLL) cells.
|
25425665 |
2014 |
|
Autoimmune Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Autoimmune disorder phenotypes in Hvcn1-deficient mice.
|
23231444 |
2013 |
|
Nephritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the present paper we show that Hvcn1 (voltage-gated hydrogen channel 1)-knockout mice show splenomegaly, autoantibodies and nephritis, that are reminiscent of human autoimmune diseases phenotypes.
|
23231444 |
2013 |
|
Virus Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Upon viral infection this was remarkably enhanced in Hvcn1-deficient mice.
|
23231444 |
2013 |
|
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Clinicopathological and biological significance of human voltage-gated proton channel Hv1 protein overexpression in breast cancer.
|
22367212 |
2012 |
|
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Clinicopathological and biological significance of human voltage-gated proton channel Hv1 protein overexpression in breast cancer.
|
22367212 |
2012 |
|
Osteosarcoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
These data suggest that mtDNA mutations within the D-Loop region, particularly the HV I and HV II segments, are a frequent event in osteosarcomas.
|
16242839 |
2006 |